Uitgangsvraag

Applied relaxation bij gegeneraliseerde angststoornis bij volwassenen.

Aanbeveling

Effectiviteit

Applied relaxation kan worden toegepast bij GAS wanneer cognitieve therapie niet beschikbaar is of wanneer die behandeling om één of andere reden is gecontraindiceerd.

 

Duur en wijze van toepassing

Applied relaxation kan in een kortdurend tijdbestek en in een individueel format bij GAS zinvol worden toegepast.

 

Duurzaamheid

Gezien de beter onderbouwde lange termijn effecten van cognitieve therapie ten opzichte van applied relaxation moet cognitieve therapie bij GAS de voorkeur verdienen boven applied relaxation.

Inleiding

Vergeleken met de meeste andere angststoornissen bestaan er betrekkelijk weinig onderzoeksgegevens over psychologische interventies bij GAS. Toch is een drietal reviews en meta analyses verschenen: Chambless & Gillis, Borkovec & Whisman, Gould et al. Hieruit blijkt dat cognitieve gedragstherapie de meest effectieve psychologische interventie is bij de behandeling van GAS. Hoewel zowel een kortdurende psychoanalytische als een kortdurende non-directieve interventie enig effect bleken te hebben in vergelijkende studies met cognitief-gedrags-therapeutische interventies, waren de effecten van de cognitief-gedrags-therapeutische interventies aanzienlijk groter. Hoewel veel interventies die ‘gedragstherapeutisch' worden genoemd ook herkenbare cognitieve elementen bevatten en andersom, worden hieronder zoveel mogelijk de resultaten van de technieken afzonderlijk weergegeven.

Conclusies

Effectiviteit

Niveau 1

Het is aangetoond dat Applied relaxation een effectieve behandelmethode is bij GAS.

 

A2 Borkovec & Costello, 1993; Ost & Breitholtz, 2000.

 

Wijze en duur van toepassing

Niveau 3

Het is aannemelijk dat ‘applied relaxation' in een kort individueel format kan worden gegeven bij GAS.

 

A2 Öst & Breitholtz, 2000.

 

Duurzaamheid

Niveau 3

Het is aannemelijk dat de effectiviteit van applied relaxation bij GAS op de langere termijn behouden blijft.

 

A2 Öst & Breitholtz, 2000.

Samenvatting literatuur

Effectiviteit

Relaxatietraining in het algemeen blijkt redelijk effectief te zijn bij GAS. Studies vergeleken cognitieve gedragstherapie met de specifieke soort relaxatie training die applied relaxation is en non-directieve therapie. Cognitieve gedragstherapie en applied relaxation bleken het beide beter te doen dan de non directieve therapie. Andere studies vergeleken cognitieve therapie met applied relaxation bij de behandeling van gegeneraliseerde angststoornis. Beide behandelingen bleken zeer effectief en er was geen verschil tussen de behandelingen.

 

Duur en wijze van toepassing

Applied relaxation is een coping en relaxatie techniek die is ontwikkeld en beschreven. Stapsgewijs leert een patiënt zich te ontspannen en dit uiteindelijk toe te passen in angstverwekkende situaties. De eerste stap is het aanleren van progressieve relaxatie, waarbij een patiënt leert spiergroepen aan te spannen en te ontspannen. De tweede stap is het ontspannen zonder aan te spannen. De volgende derde stap is het leren ontspannen met behulp van een woord (cue controlled relaxation), zoals ‘rustig', ‘ontspan' of ‘laat los'. In de vierde stap van de training leert men dit te gebruiken in allerlei situaties, zodat het gevoel van ontspanning kan generaliseren naar verschillende situaties op verschillende levensgebieden. Bij de vijfde en laatste stap leert de patiënt de ontspanning tot te passen in de moeilijke situaties zelf.

De behandeling beslaat doorgaans zo'n 12 sessies. Bij GAS is applied relaxation in een individueel format toegepast.

 

Duurzaamheid

Uit het onderzoek van blijkt dat bij een follow-up na 1 jaar er geen terugval is bij de behandeling met applied relaxation.

Zoeken en selecteren

Voor de literatuur is gezocht in: National Library of Medicine (Medline) en Psychological Abstracts (Psychinfo). Er is gezocht met de steekwoorden: general anxiety disorder, psychotherapy, cognitive behaviour therapy, review, meta-analysis en RCT. Waar nodig is gebruik gemaakt van aanvullende, niet systematisch gezochte literatuur.

Referenties

  1. Abramowitz JS. (1998). Does cognitive-behavioral therapy cure obsessive-compulsive disorder? A meta-analytic evaluation of clinical significance. Beh Ther; 29: 339-355.
  2. Abramowitz JS. (1997). Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: A quantitative review. J Cons & Clin Psychol; 65: 44-52.
  3. Abramowitz JS. (1996). Variants of exposure and response prevention in the treatment of obsessive-compulsive disorder: A meta-analysis. Behav Ther; 27: 583-600.
  4. Akhondzadeh S,et al (2001). Passionflower in the treatment of generalized anxiety: a pilot double-blind andomized controlled trial with oxazepam. J Clin Pharm Ther Oct;26 (5):363-7.
  5. Allgulander C, Hackett D, Salinas E. (2001). Venlafaxine extended release in the treatment of generalized anxiety disorder, 24 week placebo-controlled dose-ranging study. Br J Psychiatry; 179: 15-22.
  6. Allgulander C. (1999). Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand; 1000(3):193-198.
  7. Ameringen MA van, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM et al. (2001) Sertraline treatment of generalized social phobia: A 20-week, double-blind, placebo-controlled study. Am J Psychiatry; 158(2):275-281.
  8. Andrews, G., Crino, R., Hunt, C., Lampe, L., & Page, A. (1994). The treatment of anxiety disorders. Clinicianüs guide and patiënt manuals. Cambridge, Cambridge University Press.
  9. Ang-Lee MK, Moss J, Yuan CS. (2001.) Herbal medicines and perioperative care. JAMA. Jul 11; 286(2): 208-16. Review.
  10. Argento A, Tiraferri E, Marzaloni M. (2000). Oral anticoagulants and medicinal plants. An emerging interaction. Ann Ital Med Int Apr-Jun;15(2):139-43.
  11. Arntz, A. & Elgersma, H. (1999). Cognitieve therapie bij gegeneraliseerde angststoornis. In: S.M. Bögels & P. Van Oppen, Cognitieve therapie: theorie en praktijk. Houten: Bohn, Stafleu, Van Loghum.
  12. Arrindell, W.A. (1993). The fear of fear concept: evidence in favour of multidimensionality. Behaviour Research and Therapy, 31,507-518.
  13. Arrindell, W.A. (1980). Dimensional structure and psychopathology correlates of the Fear Survey Schedule (FSS ?III) in a phobic population: A factorial definition of agoraphobis. Behaviour Research and Therapy, 18, 229-242.
  14. Arrindell, W.A., & Ettema, J.H.M. (1986). SCL-90, Handleiding bij een multidimensionele psychopathologie indicator. Lisse: Swets & Zeitlinger.
  15. Arrindell, W.A., Emmelkamp, P.M.G., & Ende, J. van der (1984). Phobic dimensions: I. Reliability and generalizability across samples, gender, nations. Advances in Behavioral Research and Therapy, 6, 207-254.
  16. Arrindell, W.A., Groot, P.M. de, & Walburg, J.A. (1984). Schaal voor Interpersoonlijk Gedrag. Handleiding Deel I. Lisse: Swets & Zeitlinger.
  17. Arts, W., Severijns, R., Hoogduin, C.A.L., Haan, E. de en Schaap, C. (1990). De Inventarisatielijst Dagelijkse Bezigheden (IDB): een replicatie onderzoek naar betrouwbaarheid en validiteit. Gedragstherapie, 23, 17-27.
  18. Avia, M.D., Ruiz, M.A., Olivares, M.E., Crespo, M., Guisado, A.B., Sanchez, A. & Valera, A. (1996). The meaning of psychological symptoms: effectiveness of a group intervention with hypochondriacal patiënts. Behaviour Research and Therapy, 34, 23-32.
  19. Baer L, Rauch SL, Ballantine HT, Martuza R, e.o. (1995). Cingulotomy for intractable obsessive-compulsive disorder. Arch of Gen Psychiatry; 52: 384-392.
  20. Baghai T, Kuhn K, Ehrentraut S. (1998). Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatiënts. Psychopharmacol; 136: 357-366.
  21. Bakker A, Balkom AJLM van, Spinhoven P, Blaauw B, Dyck R van. (1998). Follow-up on the treatment of panic disorder with or without agoraphobia. J Ner Ment Dis;186:414-419.
  22. Bakker A, van Dyck R, Spinhoven Ph, van Balkom AJLM. (1999). Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry; 60: 831-838.
  23. Bakker, A., van Balkom, A.J.L.M, Spinhoven, Ph. e.a., (1998). Follow-up on the treatment of panic disorder with or without agoraphobia: a quantitative review. Journal of Nervous and Mental Disease, 186, 414-419.
  24. Bakker, A., van Balkom, A.J.L.M., Spinhoven, Ph. (2001). SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002 Sep;106(3):163-7.
  25. Bakker, A., van Balkom, AJLM, Spinhoven, Ph., Blaauw, B., van Dyck, R. (1998): Follow-up on the treatment of panic disorder with or without agoraphobia. A quantitative review. Journal of Mental and Nervous Disease, 186, 414-419.
  26. Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M. (1999). Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry; 175:120-126.
  27. Baljon, M., Kramers, M., & Verveld S. (1999). Waar woorden tekort schieten. Tijdschrift voor Kreatieve therapie vol 2 pp 3n9.
  28. Balkom A.J.L.M. van, Haan, E. de, Oppen, P. van, Spinhoven, Ph., Hoogduin, C.A.L., Dyck, R. van (1998). Cognitive and behavioral thearpies vesus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis; 186: 492-499.
  29. Balkom AJLM van, Nauta M, Bakker A. (1995). Meta-analysis on the treatment of panic disortder with agoraphobia: review and re-examination Clin Psychol Psychother; 2: 1-14.
  30. Balkom, A.J.L.M. van, Bakker, A., Spinhoven, Ph. (1997). A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. Journal of Nervous and Mental Disease, 185, 510-516.
  31. Balkom, AJLM van, van Oppen P, Vermeulen AWA, van Dyck R, Nauta MCE, Vorst HCM. (1994). A meta-analysis on the treatment of obsessive-compulsive disorder: A comparison of antidepressants, behavior and cognitive therapy. Clin Psychol Rev; 14: 359-381.
  32. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. (1998). Double-blind, fixed dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry; 155: 36-42.
  33. Ballenger JC. (1991). Long-term treatment of panic disorder. J Clin Psychiatry: 52(suppl 2): 18-23.
  34. Barlow DH, Gorman JM, Shear MK, Woods SW. (2000). Cognitive-behavioral therapy, imipramine, or their combination for panic disorder. A randomized controlled trial. JAMA, 283: 2529-2536.
  35. Barlow, D.H. (1988). Anxiety and its disorders. The nature and treatment of anxiety and panic. New York, The Guilford Press
  36. Barlow, D.H., & Cerny, J.A. (1988): Psychological treatment of panic. New York, The Guilford Press.
  37. Barlow, D.H., Rapee, R.M. & Brown, T.A. (1992). Behavioral treatment of generalized anxiety disorder. Behavior Therapy, 23, 551-570.
  38. Beaubrun G, Gray GE. (2000). A review of herbal medicines for psychiatric disorders. Psychiatr Serv. Sep;51(9):1130-4.
  39. Bech, P., Kastrup, M, Rafaelsen O.J. (1986). Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiat Scand., 73, 1-37.
  40. Beck, Rawlins, & Williams (1991). Mental Health Psychiatric Nursing.
  41. Bellew KM, McCafferty JP, Iyngar MK, Zaninelli R. (2001). Paroxetine and the rate of remission in the treatment of GAD. Poster nr 605 APA.
  42. Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P (2000). Double-blind placebo-cotrolled pilot study of paroxetine for specific phobia. Psychopharmacology (Berlin) 149, p. 194-196.
  43. Beurs E de, Balkom AJLM van, Dyck A van, Lange A. (1999). Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up. Act Psych Scand; 99:559-67.
  44. Beurs E de, Balkom AJLM van, Lange A, Koele P, Dyck R van (1995). Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo and psychological panic management combined wit exposure and exposure in vivo alone. Am J Psychiatry;152:683-691.
  45. Beurs, E. de, Dyck, R van, Balkom, A.J.L.M. van, & Lange, A. (2001): Geven Drandomised controlled trialsn de goede informatie voor de klinische praktijk? Tijdschrift voor Psychiatrie, 43, 41-48.
  46. Black DW, Wesner R, Bowers W, Gabel J. (1993). A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry; 50; 44-50.
  47. Blomhoff S, Haugt T, Hellström K, Holme I, Humble M, Matdsdu HP, Wold JE. (2001). Randomized controlled general practice trial of sertraline, exposure therapy and combined treatment in generalized social phobia. Br J Psychiatry,179:23-30.
  48. Borcovec, T.D., & Whisman, M.A. (1996).: Psychosocial treatments for generalized anxiety disorder. In: M. Mavissakalian & R. Prien (eds.): Long-term treatment of anxiety disorders. Washington D.C. American Psychiatric Association.
  49. Borkovec, T.D. & Costello, E. (1993). Efficacy of applied relaxation and cognitive-behavioural therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology, 61,611-61.
  50. Borkovec, T.D., & Mathews, A. (1988). Treatment of nonphobic anxiety disorders: A comparison of nondirective, cognitive, and coping desensitization therapy. Journal of Consulting and Clinical Psychology, 56, 877-884.
  51. Borkovec, T.D., Mathews, A.M., Chambers, A., Ebrahimi, S., Lytle, R., & Nelson, R. (1987). The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety. Journal of Consulting and Clinical Psychology, 55, 883-888.
  52. Bouman, T.K. & De Ruiter, C. (1991). De validiteit van de Anxiety Disorders Interview Schedule Revised (ADIS-R). Gedragstherapie, 2, 77-88.
  53. Bouman, T.K. & Visser, S. (1998). Cognitive and behavioural treatments of hypochondriasis. Psychotherapy and Psychosomatics, 436, 214-221.
  54. Brady K, Pearlstein T, Asnis G, Baker D, Rothbaum B, Sikes CP, Farfel GM. (2000). Efficacy and safety of Sertraline treatment of posttraumatic stress disorder. A randomized controlled trial. JAMA; 283: 1837-1844.
  55. Bram P, Greenberg D, Dasberg H, Lezer B. (1990). Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry; 51: 236-238.
  56. Broeke, E. ten, Jongh, A. de, Wiersma, K., Gimbrère, F. (1997). Psychotherapie bij postraumatische stressstoornis: de stand van zaken. Tijdschrift voor Psychotherapie, 23, 305-328.
  57. Brom, D. & Kleber, R.J. (1985). De Schok Verwerkings Lijst. Nederlands Tijdschrift voor de Psychologie, 40, 164-168.
  58. Brooks D, Stark A, (1989). The effects of dance/movement therapy on affect: A pilot study. American Journal of Dance Therapy, 19, 135-160.
  59. Brown, C., Chen, A., & Dworkin, S. (1989). Music in the Control of Human Pain. Music Therapy, 8, 1,47-60.
  60. Brown, T.A., OüLeary, T., & Barlow, D.H. (1994): Generalized anxiety disorder. In: D.H. Barlow (ed.): Clinical handbook of psychological disorders. Second edition. New York, The Guilford Press.
  61. Brown,T.A., Hertz, R.M., & Barlow, D.H. (1992). New developments in cognitive-behavioral treatment of anxiety disorders. American-Psychiatric-Press-Review-of-Psychiatry, 11,285-306.
  62. Bruce, T., Spiegel, D., & Hegel, M. (1999).: Cognitive behavioral therapy helps prevent relapse and recurrence of panic disorder following alprazolam discontinuation: a long-term follow-up of the Peoria and Dartmouth studies. Journal of Consulting and Clinical Psychology, 67, 151-156.
  63. Burrows GD, Judd FK, Norman TR. (1992). Long term drug treatment of panic disorder. J Psychiatr Res; 27 (suppl 1): 111-125.
  64. Butler, G., Fennell, M., Robson, Ph., e.a. (1991). Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. Journal of Consulting and Clinical Psychology, 59, 167-175.
  65. Carpenito, L.J. (2001)., Zakboek verpleegkundige diagnosen. Wolters-Noordhoff, Groningen.
  66. Chambless, D.L., & Gillis, M.M. (1993).: Cognitive therapy of anxiety disorders. Journal of Consulting and Clinical Psychology, 61,248-260.
  67. Chambless, D.L., Caputo, G.C., Bright, P., & Gallagher, R. (1984). Assessment of fear of fear in agoraphobics: the Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. Journal of Consulting and Clinical Psychology, 52, 1090-1097.
  68. Chemtob, M.C., Tolin, D.F., Van der Kolk, B.A., Pitman, R.K. (2000). Eye Movement Desensitization and Reprocessing. In: E.B. Foa, T.M. Keane, M.J. Friedman (Eds.) (2000). Effective treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies. London: Guilford.
  69. Clark DM, Salkovskis PM, Hackmann A, e.a. (1994). A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Brit J Psychiatry; 164: 759-769.
  70. Clark DM, Wells A. (2002). A cognitive model of social phobia. Heimberg, R. G., Liebowitz, M., Hope, D. A., and Schneier, F. R. In: Social Phobia: Diagnosis, Assessment and Treatment.
  71. Clark, D.M. (1996): Panic disorder: from theory to therapy. In: P.M. Salkovskis (ed.): Frontiers of cognitive therapy. New York, The Guilford Press.
  72. Clark, D.M., Salkovskis, P.M., Hackmann, A., Wells, A., Fennell, M., Ludgate, J., Ahmad, S., Richards, H.C. & Gelder, M. (1998). Two psychological treatments for hypochondriasis. British Journal of Psychiatry, 173, 218-225.
  73. Clum, G.A., Clum, G.A., & Surls, R. (1993): A meta-analysis of treatments for panic disorder. Journal of Consulting & Clinical Psychology, 61,317-326.
  74. Cohn JB, Rickels K. (1989). Pooled double-blind comparison of the effects of buspirone,diazepam and placebo in women with chronic anxiety. Current Medical Research Opinions; 11: 305-320.
  75. Cohn JB, Wilcox CS. Longterm comparison of alprazolam, lorazepam and placebo in patiënts with an anxiety disorder. Psychopharmacology 1984;4:93-98.
  76. Connor KM, Davidson JRT, Potts NLS. (1998). Discontinuation of clonazepam in the treatment of social phobia. J Clin Psycopharmacology; 18: 373-378.
  77. Connor KM, Sutherland SM, Tupler LA, et al. (1999). Fluoxetine in post-traumatic stress disorder: a randomised, double-blind study. Br J Psychiatry; 175:17-22.
  78. Cottraux, J., Mollard, E., Bouvard, M. & Marks, I. (1993). Exposure therapy, fluvoxamine, or combination treatment in obsessive Dcompulsive disorder: One year follow Gup. Psychiatry Res; 49: 63-5.
  79. Cottraux, J., Mollard, E., Bouvard, M., Marks, I., Sluys, M., Nury, A. M., Douge, R. & Ciadella, P. (1990). A controlled study of fluvoxamine and exposure in obsessive Dcompulsive disorder. Int Clin Psychopharmacol; 5: 17ó0.
  80. Cox BJ, Swinson RP, Morrison B, Lee PS. (1993). Clomipramine, fluoxetine and behavior therapy in the treatment of obsessive-compulsive disorder: A meta-analysis. J Behav Ther & Exp Psychiat; 24: 149-153.
  81. Cox, B.J., Endler, N.S., Lee, P.S., & Swinson, R.P. (1992): A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam and in vivo exposure. Journal of Behavior Therapy & Experimental Psychiatry, 23, 175-182.
  82. Craske MG, Rowe M, Lewin M, Noriega Dimitri R, (1997). Interoceptive exposure versus breathing retraining within cognitive-behavioural therapy for panic disorder with agoraphobia, Brit. Journ. of Clin Psychology, 36: 85-99 Part 1 FEB.
  83. Craske, M.G. (1999): Anxiety disorders. Psychological approaches to theory and treatment. Boulder, Westview Press.
  84. Craske, M.G., & Rowe, M.K. (1997). A comparison of behavioral and cognitive treatments of phobias. In : G.C.L. Davey (ed.): Phobias. A handbook of theory, research and treatment. Chichester, New York.
  85. Cross-National Collaborative Panic Study. (1992). Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry; 160: 191-202.
  86. Curtis GC, Massana J, Udina C, et al. (1993). Maintanance drug therapy in panic disorder. J Psychiatr Res; 27(suppl 1):111-125.
  87. Cutler NR, Sramek JJ, Keppel-Hesselink JM, et al. (1993). A doubleblind placebo-controlled study comparing the efficacy and safety of ypsapirone versus lorazepam in patiënts with generalized anxiety disorder: a prospective multi-centred trial. J Clin Psychopharmology; 13: 429-437.
  88. Dam-Baggen R, Kraaimaat F. (2000). Group social skills training or cognitive group therapy as the clinical treatment of choice for generalized social phobia? J Anxiety Disord 14: 437-51.
  89. Dam-Baggen, C.M.J. van, & Kraaimaat, F. (1990). IOA. Herziene handleiding. Deel 2. Lisse: Swets & Zeitlinger.
  90. Data on file, GlaxoSmithKline.
  91. Davidson JRT. (2000). Pharmacotherapy of post-traumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. J Clin Psychiatry; 61 suppl.5: 52-56.
  92. Davidson J, Kudler H, Smith R, et al. (1990). Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry; 47: 259-266.
  93. Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J, Maddock R, Hegel MT, Farfel G. (2001). Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry; 158: 1974-1981.
  94. Davidson JR, Weisler RH, Malik M, et al. (1998). Fluvoxamine in civilians with posttraumatic stress disorder (letter). J Clin Psychopharmacol; 18: 93-95.
  95. Davidson JRT, DuPont RL, Hedges D, Haskins JT. (1999). Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatiënts with generalized anxiety disorder. J Clin Psychiatry; 60: 528-535.
  96. Davidson JRT, Ford SN, Smith RD. (1991). Long-term treatment of social phobia with clonazepam. J Clin Psychiatry;11(suppl): 16-20.
  97. Davidson JRT, Potts N, Richichi. (1993). Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacology; 13: 423-428.
  98. Davidson, P.R., Parker, K.C. (2001). Eye Movement Desensitization and Reprocessing (EMDR): A meta-analysis. Journal of Consulting and Clinical Psychology, 69, 305-316.
  99. De Araujo LA, Ito LM, Marks IM, Deale A. Does imagined exposure to the consequences of not ritualising enhance live exposure for OCD? A controlled study. Brit J Psychiat 1995;167:65-70.
  100. De Silva, P., & Rachman, S. (1984).: Does escape behaviour strenghten agoraphobic avoidance? A preliminary study. Behaviour Research & Therapy, 22, 87-91.
  101. Derogatis, L.R. (1977). SCL-90 Administration, scoring and procedures manual 1 for the R(evised) version and other instruments of the psychopathology rating scale series. Baltimore, MD.: Clinical Psychometrics Research Unit, Johns Hopkins University School of Medicine.
  102. Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. (1986). Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry; 4: 458-460.
  103. Durham, R.C., Fisher, P.L., Treliving, L.R., Hau, C.M., Richard, K., & Stewart, J.B. (1999).: One year follow-up of cognitive therapy, analytic psychotherapy and anxiety management training for generalized anxiety disorder: symptom change, medication usage and attitudes to treatment. Behavioural and cognitive psychotherapy, 27, 19-35.
  104. Durham, R.C., Murphy, T., Allan, T., e.a. (1994). Cognitive therapy, analytic psychotherapy an anxiety management training for generalised anxiety disorder. British Journal of Psychiatry, 165, 315-323.
  105. E. Broers & J. de Lange (1998). Hulpverlening bij zelfverwonding in de psychiatri.e LCVV, Trimbosinstituut, Utrecht.
  106. E. Broers & J. de Lange (1999). Omgaan met snijdende pijn, verpleegkundige interventies bij zelfverwondend gedrag. LCVV, Trimbosinstituut.
  107. E. Broers & Weeghel, J. van (2000). Afzien van suïcide, hoe verpleegkundigen suÏcidale mensen begeleiden. Trimbos instituut, Utrecht.
  108. Edelmann, R.J. (1992).: Anxiety. Theory, research, and interventionin clinical and health psychology. Chichester, John Wiley and Sons.
  109. Ellie R, Lamontagne Y. (1984). Alprazolam en diazepam in the treatment of generalized anxiety. J Clin Psychopharmacology; 4 (3): 125-129.
  110. Emmelkamp PMG, Beens H. (1991). Cognitive therapy with OCD. Behav Res & Ther; 29: 293-300.
  111. Emmelkamp PMG, Kraanen J. (1977). Therapist controlled exposure in vivo versus self-controlled exposure in vivo: a comparison with obsessive-compulsive patiënts. Behav Res & Ther; 15: 491-495
  112. Emmelkamp PMG, Visser S, Hoekstra RJ. (1988). Cognitive therapy versus exposure in vivo in the treatment of obsessive-compulsives. Cogn Ther & Res; 12: 103-114.
  113. Emmelkamp PMG. (2001). Behavior therapy with adults. In: Bergin AE, Garfield SL. Handbook of psychotherapy and behavor change. 5th ed. New York: Wiley;:
  114. Emmelkamp, P.M.G. (1994).: Behavior therapy with adults. In: A.E. Bergin & S.L. Garfield (eds.): Handbook of psychotherapy and behavior change, 4th Edition. New York, John Wiley and Sons.
  115. Emmelkamp, P.M.G., Hoogduin, C.A.L., & Hout, M.A. van den (2000).: Angststoornissen. In: W. Vandereycken, C.A.L. Hoogduin & P.M.G. Emmelkamp (red.) Handboek psychopathologie deel 1. Houten, Bohn Stafleu Van Loghum.
  116. Emmelkamp, P.M.G., van Balkom, A.J.L. (1996).: Angststoornissen. In: W. Vandereycken, C.A.L. Hoogduin & P.M.G. Emmelkamp (red.): Handboek psychopathologie deel 3. Houten, Bohn Stafleu Van Loghum.
  117. Emmelkamp, PMG & Felten, M. (1985). The process of exposure in vivo: Cognitive and physiological changes during treatment of acrophobia. Behaviour Research & Therapy, 23, 219-223
  118. Enkelmann R. (1991). Alprazolan versus buspirone in the treatment of outpatiënts with generalized anxiety disorder. Psychopharmacology; 105: 428-432.
  119. Eppley e.a. (1989). Differential effects of relaxation techniques on trait anxiety: A meta-analysis. J Clin Psychol, Nov 1989, 45(6):957-974.
  120. Ernst E. (2002 ). The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng Echinacea, Saw Palmetto, and Kava. Ann Intern Med. Jan 1;136(1):42-53. Review.
  121. Etten, M.L. van, Taylor, S. (1998). Comparative efficacy of treatments for posttraumatic stress disorder: A meta-analysis. Clinical psychology and psychotherapy, 5, 126-144.
  122. Evers, A., Vliet-Mulder, J.C. van, & Groot, C.J. (2000). Documentatie van tests en testresearch in Nederland. Assen: Van Gorcum.
  123. Fallon, B.A., Schneier, F.R., Marshall R. et al. (1996). The pharmacotherapy of hypochondriasis. Psychopharmacollogy Bulletin; 32; 607-611.
  124. Fals-Stewart W, Marks AP, Schafer B. (1993). A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder. J Nerv & Ment Dis; 181:189-193.
  125. Farmacotherapeutisch Kompas 2000/2001.
  126. Fedoroff IC, Taylor S. (2001). Psychological and pharmacological treatments of social phobia: a meta- analysis. J Clin Psychopharmacol 21: 311-24.
  127. Feighner JP. (1987). Buspirone in the long-term treatment in generalized anxiety disorder. J Clin Psychiatry; 48: 3-6.
  128. Ferguson, E. & Daniels, E. (1995). The Illness Attituide Scales (IAS): A psychometric evaluation in a non-clinical sample. Personality and Individual Differences, 18, 463-469.
  129. Feske U, Chambless DL. (1995). Cognitive-behavioral versua exposure only treatment for social phobia: a meta-analysis. Behavor Therapy 26: 695-720.
  130. First, M.B., Gibbon, M., Spitzer, R.L., Williams, J.B.W. (1996). User\'s guide for the Structured Clinical Interview for the DSM-IV Axis I disorders - research version. New York: Biometrics Research Department, New York State Psychiatric Institute.
  131. Foa EB, Kozak MJ, Goodman WK, Hollander E, Jenike MA, Rasmussen S. (1995). DSM-IV field trial: Obsessive compulsive disorder. Am J Psychiat; 152: 90-96.
  132. Foa EB, Steketee G, Milby JB. (1980). Differential effects of exposure and response prevention in obsessive-compulsive washers. J Cons & Clin Psychol ; 48 : 71-79.
  133. Foa EB, Steketee GS, Grayson JB, Turner RM, Latimer PR. (1984). Deliberate exposure and blocking of obsessive-compulsive rituals : Immediate and long term effects. Beh Ther; 15: 450-472.
  134. Foa, E.B., Keane, T.M., Friedman, M.J. (Eds.) (2000). Effective treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies. London: Guilford.
  135. Franklin ME, Abramowitz JS, Kozak MJ, Levitt JT, Foa EB. (2000). Effectiveness of exposure and ritual prevention for obsessive-compulsive disorder: randomized compared with nonrandomized samples. J Cons & Clin Psychol; 68: 594-602.
  136. Freeston MH, Ladouceur R, Gagnon F, Thibodeau N, Rheaume J, Letarte H, Bujold A. (1997). Cognitive behavioural treatment of obsessive thoughts: A controlled study. J Cons & Clin Psychol ; 65 : 405-423.
  137. Gagne, D. & Toye, R.C. (1994). The effects of therapeutic touch and relaxation therapy in reducing anxiety, vol. 8, pp. 184-189.
  138. Garssen B, De Ruiter C, van Dyck R. (1992). Breathing retraining a rational placebo, Clinical Psychology Review, Vol 2 (2): 141-153.
  139. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. (2000). Efficacy of venlafaxine extended release capsules in nondepressed outpatiënts with generalized anxiety disorder. 6-month randomized controlled study. JAMA; 283: 3082-3088.
  140. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ. (1991). Cognitieve- behavioural and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry; 48: 938-945.
  141. Gentile V, Lotufo-Neto F, Andrade L. Clomipramine (1993). A better reference drug for panicagoraphobia. 1. Effeciveness comparison with imipramine. J Psychopharmacol; 7: 316-324.
  142. Gerven, M. van. (1996). De dynamiek tussen angst en verlangen; tijdschrift voor kreatieve therapie 1996-1.
  143. Gilroy, L.J., Kirby, K.C., Daniels, B.A., Menzies, R.G., & Montgommery, I.M. (2000). Controlled comparison of computer-aided vicarious exposure versus life exposure in the treatment of spider phobia. Behavior Therapy, 31,733-744.
  144. Glas, J., (1988). Tekenen naar de overkant. Tijdschrift voor kreatieve therapie, vol 3., pp 68-74.
  145. Goldberg HL, Finnerty RJ. (1979). The comparitive efficacy of buspirone and diazepam in the treatment of anxiety. American J Psychiatry; 136: 1184-1187.
  146. Goldberg, D., Bridges, K., Duncan-Jones, P., & Grayson, D. (1988). Detecting anxiety and depression in general medical settings. British Medical Journal, 297, 897-899.
  147. Goodman WK, Kozak MJ, White KL. (1996). Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind placebo-controlled trial. Int Clin Psychopharmacol; 11: 21-29.
  148. Gordon, M. (1997). Handleiding verpleegkundige diagnostiek1997-1998. Elsevier/ De Tijdstroom.
  149. Gould RA, Buckminster S, Pollack MH, Otto MW, Yap L. (1997). Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clinical Psychology: Science and practice 4: 291-306,.
  150. Gould, R.A., Otto, M.W., Pollack, M.H. & Yap, L. (1997): Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. Behavior Therapy, 28, 285-305.
  151. Greist J, Chouinard G, Duboff E, Halaris A, Won Kim S, Koran L, Liebowitz M, Lydiard B, Rasmussen S, White K, Sikes C. (1995). Double-blind parallel comparison of three dosages sertraline and placebo in outpatiënts with obsessive-compulsive disorder. Arch Gen Psychiatry; 52: 289-295.
  152. Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz MR, Lydiard B, McElroy S, Mendels J, Rasmussen S, White K, Flicker C. (1995). A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol; 10: 57-65.
  153. Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. (1995). Efficacy and tolerability of serotonin transport inhibitors on obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry; 52: 53-60.
  154. Groenestijn, M.A.C. van, Akkerhuis, G.W., Kupka, R.W., Schneider, N. & Nolen, W.A. (1999). Gestructureerd klinisch interview voor de vaststelling van DSM-IV As-I stoornissen. Lisse: Swets en Zeitlinger.
  155. Haan E de, Oppen P van, Balkom AJLM van, Spinhoven P, Hoogduin KAL, Dyck R van (1997). Prediction of outcome and early vs. late improvement in OCD patiënts treated with cognitive behaviour therapy and pharmacotherapy. Acta Psychiat Scand; 96: 354-361.
  156. Hagood, M.M., (2000). The use of art in counselling child and adult survivors of sexual abuse. London: Jessica Kingsley Publishers.
  157. Hanser, S. (1985). Music therapy and stress reduction research. Journal of Music therapy, 22, 193-206.
  158. Hattum M e.a. (2000). Vakwerk producttypering van vaktherapeuten voor het programma stemmingsstoornissen.
  159. Heimberg RG, Dodge CS, Hope DA, Kennedy CR, Zollo LJ, Becker RE. (1990). Cognitive behavioural group treatment for social phobia: comparison with a credible placebo control. Cognitive Therapy and Research; 14: 1-23.
  160. Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, Liebowitz MR (1999). Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med 29: 199-212,.
  161. Heimberg RG, Salzman D, Holt CS, Blendell K. (1993). Cognitive-behavioural group treatment for social phobia: effectiveness at five-year folow-up. Cognitive therapy and Research 17: 325-39,.
  162. Heimberg RG. (2002). Cognitive-behavioral therapy for social anxiety disorder: current status and future directions. Biol Psychiatry 51: 101-8.
  163. Hellendoorn J., Groothoff, E., Mostert P., & Harinck, F., (1992). Beeldcommunicatie, een vorm van kinderpsychotherapie. Deventer: Bohn Stafleu Van Loghum.
  164. Hertzberg MA, Butterfield MI, Feldman ME et al. (1999). A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry; 45: 1226-1229.
  165. Hiss H, Foa EB, Kozak MJ. (1994). Relaps prevention program for treatment of obsessive-compulsive disorder. J Cons & Clin Psychol; 62: 801-808.
  166. Hodgson, R., & Rachman, S. (1977). Obsessional-compulsive complaints. Behaviour Research and Therapy, 15, 389-395.
  167. Hoehn-Saric R, McLeod DR, Hipsley PA. (1993). Effect of fluvoxamine in panic disorder. J Clin Psychopharmacol; 13: 321-326.
  168. Hoehn-Saric R, McLoud DR, Zimmerli WD. (1988). Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry; 49: 293-301.
  169. Hoeksma BH, ICL Bastings, HBI de Lange, R de Meij. (1995). Tijdsbesteding in RIAGGus en psychiatrische poliklinieken. Enschede: Hoeksma, Homans & Menting, organisatieadviseurs,41.
  170. Hofmann SG, Newman MG, Ehlers A, Roth WT. (1995). Psychophysiological differences between subgroups of social phobia. J Abnorm Psychol 104: 224-31.
  171. Hohagen, F., Winkelmann, G., Rasche-Rauchle, H., Hand, I., König, A., Münchau, N., Hiss, H., Geider-Kabisch, C., Kappler, C., Schramm, P., Rey, E., Aldenhoff J., & Berger, M. (1998). Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry; 173 (suppl 35): 71-78.
  172. Holland RI, Fawcett J, Hoehn-Saric R. (1994). Long-term treatment of panic disorder with fluvoxamine in outpatiënts who had completed double-blind trials. Neuropsychopharmacol; 10 (suppl 3): 102.
  173. Hollister LF. (1977). Valium: a discussion of current issues. Psychosomatics; 18: 45-58.
  174. Horowitz, M., Wilner, N., Alvarez, W. (1979). Impact of Event Scale: A measure of subjective stress. Psychosom Med, 41,209-218.
  175. Houghton PJ. (1999). The scientific basis for the reputed activity of Valerian. J.Pharm Pharmacol May;51(5):505-12.
  176. Hovens, J.E., Ploeg, H.M. van der, Bramsen, I., Klaarenbeek , M.T.A., Schreuder, J.N. & Rivero, V.V. (1994). The development of the self-rating inventory for posttraumatic stress disorder. Acta Psychiatrica Scandinavica, 90, 172-183.
  177. Hutschemakers G, Camp van der K, van Hattum M. (2001). Psychotherapie in getallen. Utrecht: Trimbos-instituut,.
  178. Ironson, G., Freund, B., Strauss, J.L., & Williams (2002). Comparison of two treatments for traumatic stress: A community based study of EMDR and prolonged exposure. Journal of Clinical Psychology, 58, 113-128.
  179. Izzo AA, Ernst E. (2001). Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs.;61(15):2163-75.
  180. James I, Savage I. (1984). Beneficial effect of nadolol on anxietyDinduced disturbances of performance in musicians: a comparison with diazepam and placebo. Am Heart J; 108: 1150-1155.
  181. Janzing, C. & Kerstens, J. (1984). Groepsgericht werken in een therapeutisch milieu. Stafleu, Alphen a/d Rijn.
  182. Jenike MA, Baer L, Ballantine HT, e.o. (1991). Cingulotomy for refractory obsessive-compulsive disorder: a long-term follow-up of 33 ptns. Arch Gen Psychiatry; 48: 548-553.
  183. Jeremalm, A., Jansson, L. Öst, L-G (1986). Individual response patterns and the effects of different behavioral methods in the treatmentof dental phobia. Behaviour Research & Therapy, 24, 587-596.
  184. Johnson, D.R. (1981).: DDramatherapy and the schizophrenic conditionü; in: Drama in Therapy, edited by Schattner, G. and Courtney, R.; New York: Drama book specialists, 47-64.
  185. Jongh, A. de, Muris, P., ter Horst, G., van Zuuren, F., Schoenmakers, N. & Makkes, P. (1995).: One-session cognitive treatment of dental phobia: preparing dental phobics for treatment by restructuring negative cognitions. Behaviour Research & Therapy, 33, 947-954.
  186. Jonghe F & J. Swinkels. Antidepressiva (2001). Een leidraad voor het rationeel omgaan met antidepressiva bij de behandeling van patiënten met een depressie. Amsterdam: Benecke NI, 2001.
  187. Kahans, D. & Calford, M.B. (1982). The influence of music on psychiatric patiënts\' immediate attitude change toward therapists. Journal of Music Therapy, 19, 3, 179-187
  188. Kasvikis, Y., Marks, I.M. (1988). Clomipramine, selfDexposure, and therapist Daccompanied exposure in obsessive Dcompulsive ritualizers: Two Dyear follow Dup. Journal of Anxiety Disorders; 2: 291Ó98.
  189. Kellner, R. (1987). Somatization and hypochondriasis. New York: Praeger.
  190. Klosko JS, Barlow DH, Tassinari R, e.a. (1990). A comparison of alprazolam and behavior therapy in treatment of panic disorder. J Consult Clin Psychology; 58: 77-84.
  191. Klungers, J. (2002). Suïcide. In: Effectief verplegen, deel 2, p.145-174 KAVANAH, Dwingeloo.
  192. Kobak KA, Greist JH, Jefferson JW, Katzelnick, DJ, Henry J. (1998). Behavioral versus pharmacological treatments of obsessive-compulsive disorder: A meta-analysis. Psychopharm.; 136: 205-216.
  193. Kolk BA van de, Dreyfuss D, Michaels M, et al. (1994). Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry; 55: 517-522.
  194. Kolk, B.A. van der, McFarlane, A.C., Weisaeth, J.P. (Eds.) (1996). Traumatic Stress: The effects of overwhelming experience on mind, body and society. New York: Guilford.
  195. Koran LM, McElroy SL, Davidson JRT, Rasmussen SA, Hollander E, Jenike MA. (1996). Fluvoxamine versus clomipramine for obsessive-compulsive disorder: A double-blind comparison. J Clin Psychopharmacol; 16: 121-129.
  196. Kosten TR, Frank JB. Dan E, et al. (1991). Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis; 179: 366-370.
  197. Kraaimaat, F. (1994). De YInventarisatielijst Dagelijkse Bezigheden' (IDB) Gedragstherapie, 27, 149-153.
  198. Kraaimaat, F.W., & Dam-Baggen, C.M.J. van (1976). Ontwikkeling van een zelf-beoordelingslijst voor obsessieve-compulsief gedrag. Nederlands Tijdschrift voor de Psychologie, 31,201-211.
  199. Kraaykamp, H.J.M., Emmelkamp, P.M.G., & Hout, M.A. van den. (1989). The Maudsley Obsessional-Compulsive Inventory: Reliability and validity (Ongepubliceerd manuscript RUG - Klinische Psychologie).
  200. Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D, Roy-Byrne P, Phillpis K, Jeske Du Pont I. (1999). Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol; 19: 172-176.
  201. Landy, R.J. (1997).: ?Drama Therapy and Distancing: Reflections on Theory and Clinical applicationü; in: The Arts in Psychotherapy, 23, 367-372.
  202. Lazarus, R.S., Folkman. (1984). Stress, appraisal and coping. New York: Springer Publishing Comp.
  203. Lecrubier Y, Bakker A, Judge R, (1997). Collaborative Paroxetine Investigators. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand; 95: 145-152.
  204. Lecrubier Y, Judge R, (1997). The Collaborative Paroxetine Panic Study Investigators. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand; 95:153-160.
  205. Lehrer, P.M. & Woolfolk, R.L. (1982). Self-report assessment of anxiety: Somatic, cognitive and behavioral modalities. Behavioral Assessment, 4, 167-177.
  206. Lelliott, P. T., Marks, I. M., Monteiro, W. O., Tsakiris, F., & Noshirvani, H. (1987). Agoraphobics 5 years after imipramine and exposure; outcome and predictors. Journal of Nervous and Mental Disease, 175, 599Ö05.
  207. Lepola U, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, Penttinen JT, Pedersen T, Lehto HJ. (1998). A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry.; 59: 528-534.
  208. Liebowitz MR, Gorman JM, Fyer AJ. (1985). Social phobia: review of a neglected anxiety disorder. 42: 729-736.
  209. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hattener J, Fyer A, Gorman J, Papp L, Daries S, Gully R, Klein DF. (1992). Phenelzine vs atenolol in social phobia. Arch Gen Psychiatry; 49: 290-300.
  210. Liebowitz MR. (1987). Social phobia. Mod Probl Pharmacopsychiatry 22: 141-73.
  211. Linden, GJH Van der, Stein DJ, van Balkom AJLM (2000). The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): A meta-analysis of randomized controlled trials. Int Clin Psychopharmacol; 15: suppl-SUS23.
  212. Lydiard RB, Lesser LM, Ballenger JC, Rubin RT, Lararia M, Dupont R. (1992). A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol; 12: 96-103.
  213. Malchiodi, C., (1990). Breaking the silence. New York: Brunner/Mazel.
  214. Malik ML, Connor KM, Sutherland SM. (1999). Quality of life and posttraumatic stress disorder: a pilot study asssessing changes in SF-36 scores before and after treatment in a placebo-controlled trial of fluoxetine. J Trauma Stress; 12: 387-393.
  215. Malsch U, Kieser M. (2001). Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl). Sep;157(3):277-83.
  216. Marks IM. (1997). Behaviour therapy for obsessive-compulsive disorder: a decade of progress. Can J Psychiat; 42: 1021-1027
  217. Marks, I. M., Gray, S., Cohen, D., Hill, R., Mawson, D., Ramm, E. & Stern, R. (1983). Imipramine and brief therapist Daided exposure in agoraphobics having selfDexposure homework. Archives of General Psychiatry, 40, 153n62.
  218. Marks, I. M., Lelliott, P., Basoglu, M., Noshirvani, H., Monteiro, W., Cohen, D. & Kasvikis, Y. (1988). Clomipramine, self Dexposure and therapist Daided exposure for obsessive Dcompulsive rituals Br J Psychiatry 152: 522Ö34.
  219. Marks, I.M., Stern, R. S., Mawson, D., Cobb, J. & McDonald, R. (1980). Clomipramine and exposure for obsessive Dcompulsive rituals: I. Br J Psychiatry; 136: 1o5.
  220. Marks, I., Lovell, K., Noshirvani, H., Livanou, M., & Thrasher, S. (1998). Treatment of psotraumatic stress disorders by exposure and/or cognitive restructuring: A controlled study. Archives of General Psychiatry, 55, 317-325.
  221. Marks, I.M. (1987): Fears, phobias and rituals. Panic, anxiety and their disorders. New York, Oxford University Press
  222. Marks, I.M., & Mathews, A.M. (1979). Brief standard self-rating for phobic patiënts. Behaviour Research and Therapy, 17, 59-68.
  223. Marmar CR, Schoenfeld F, Weiss DS et al. (1996). Open trial of fluvoxamine treatment for combat-related Titel: Multidisciplinaire richtlijn Angststoornissen (eerste revisie) (2.0) posttraumatic stress disorder. J Clin Psychiatry (suppl 8):66-70.
  224. Marshall RD, Beebe KL, Oldham M, Zanenelli R. (2001). Efficacy and safety of paroxetine in chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry; 158: 1982-1988.
  225. Marshall RD, Schneier FR, Fallon BA, et al. (1998). An open trial of paroxetine in patiënts with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol; 18:10-18 1996.
  226. Mathews, A.M., Teasdale, J.D., Munby, M., Johnston, D.W., & Shaw, P.M. (1977): A home-based treatment program for agoraphobia. Behavior Therapy, 8, 915-924.
  227. Mattick RP, Peters L. (1988). Treatment of severe social phobia: effects of guided exposure with and without cognitive restructuring. J Consult Clin Psychol 56: 251-60.
  228. Mattick, R.P., Andrews, G., Hadzi-Pavlovic, G., & Christenson, H. (1990): Treatment of panic and agoraphobia: An integrative review. The Journal of Nervous and Mental Disease, 178, 567-576.
  229. Mavissakalian M & Perel, JM. (1992). Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry; 49: 318-323.
  230. Mavissakalian MR, Perel JM. (1995). Imipramine treatment of panic disorder with agoraphobia: Dose ranging and plasma level-reponse relationships. Am J Psychiatry; 152: 673-682.
  231. Mavissakalian, M. & Michelson, L. (1986a). Agoraphobia: Relative and combined effectiveness of therapist Dassisted in vivo exposure and imipramine. Journal of Clinical Psychiatry, 47, 117n22.
  232. Mavissakalian, M. & Michelson, L. (1986b). Two Dyear follow Dup of exposure and imipramine treatment of agoraphobia. American Journal of Psychiatry, 143, 1106n112.
  233. Mavissakalian, M., Michelson, L. & Dealy, R.S. (1983). Pharmacological treatment of agoraphobia: Imipramine versus imipramine with programmed practice. British Journal of Psychiatry, 143, 348Ó55.
  234. Mc Dougle CJ, Epperson CN, Pelton GH, Wasylink S, Prica LH (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive compulsive disorder. Arch Gen Psychiatry; 57: 794-801.
  235. Mc Dougle CJ, Price LH, Goodman WK Charney DS, Heninger FR (1991). A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy. J Clin Psychopharmacol: 11: 175-181.
  236. McCloskey, J.C. & Bulechek, G.M. (1997), Verpleegkundige interventies, Second edn, De Tijdstroom, Utrecht.
  237. McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, Heninger GR, Price LH (1993). Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry; 150: 647-649.
  238. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994). Haloperidol addition to fluvoxamine-refractory obsessive compulsive disorder. A double-blind placebo controlled study in patiënts with and without tics. Arch Gen Psychiatry; 51: 302-308.
  239. McFarland, G. K. & McFarlane, E.A. (1997). Nursing Diagnosis & Intervention, Planning for Patiënt Care. Mosby, St. Louis.
  240. McFarland, G. K. & Thomas, M.D. (1991). Psychiatric mental health nursing; Application of the nursing process. Lippincott company, Philadelphia.
  241. McFarland, G.K., Wasli, E.L., & Gerety, E.K. (1992). Nursing Diagnoses & Process in Psychiatric Mental Health Nursing, Second edition edn, Lippincott comp., Philadelphia.
  242. McFarland, G.K., Wasli, E.L., & Gerety, E.K. (1997). Nursing Diagnoses & Process in Psychiatric Mental Health Nursing, thirth ed. Lippincott, Philadelphia, New York.
  243. McLean PD, Whittal ML, Thordarson DS, Taylor S, Soechting I, Koch WJ, Paterson R, Anderson KW. (2001). Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. J Cons & Clin Psychol; 69: 205-214.
  244. McNally, R.J. (1997). Atypical phobias. In : G.C.L. Davey (ed.): Phobias. A handbook of theory, research and treatment. Chichester, New York.
  245. Meehan, Bulechek G.M., J.C. McCloskey (1992). Nursing interventions, essential nursing treatments second edition, WB Saunders company, Philadelphia,.
  246. Mersch PP, Emmelkamp PM, Lips C. (1991). Social phobia: individual response patterns and the long-term effects of behavioral and cognitive interventions. A follow-up study. Behav Res Ther 29: 357-62.
  247. Mersch PP. (1995). The treatment of social phobia: the differential effectiveness of exposure in vivo and an integration of exposure in vivo, rational emotive therapy and social skills training. Behav Res Ther 33: 259-69.
  248. Michelson D, Lydiard B, Pollack MH, Tamura RN, Hoog SI, Tepner RMAD, Tollefson GD. (1998). Outcome assessment and clinical improvement in panic disorder: Evidence from a randomized controlled trial of fluoxetine and placebo. Am J Psychiatry; 155: 1570-1577.
  249. Mindus P, Rasmussen SA, Lindquist C (1994). Neurosurgical treatment for refractory obsessive-compulsive disorder: implications for understanding frontal lobe function. J of Neuropsychiatry; 6: 467-477.
  250. Modigh K, Westberg P, Eriksson E. (1992). Superiority of clomipramine over imipramine in the treatment of panic disorder. J Clin Psychopharmacol; 12: 251-261.
  251. Montgomery SA. Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM. (2001). Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obessive-compulsive disorder. Int Clin Psychopharmacol; 16: 75-86.
  252. Mulken S, Bogels SM, de Jong PJ, Louwers J. (2001). Fear of blushing: effects of task concentration training versus exposure in vivo on fear and physiology. J Anxiety Disord 15: 413-32,.
  253. Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E. (1997). Long-term pharmacotherapy of obsessive-compulsive disorder: A double-blind controlled study. J Clin psychopharmacol; 17: 4-10.
  254. Nielzen, S. & Cesarec, Z. (1982). The effect of mental illness on the emotional experience of music. Archives Psychiatric Nervenkr, 231,6, 527-538
  255. Nondepressed outpatiënts with generalized anxiety disorder (2000). Am J Psychiatry; 157: 968-974.
  256. Noppen BL van, Pato MT, Marsland R, Rasmussen SA. (1998). A time-limited behavioral group for treatment of obsessive-compulsive disorder. J Psychother Pract & Res; 7: 272-280.
  257. North American Nursing Diagnosis Association (1999). NANDA verpleegkundige diagnoses; definities en classificatie 1999-2000. Bohn Stafleu Van Loghum.
  258. UDMathuna, D.P. (2000). Evidence-based practice and reviews of Therapeutic touch, Journal of nursing scolarship, p 279-285.
  259. OuSullivan G, Marks IM. (1990). Long-term outcome of phobic and obsessive-compulsive disorders after exposure: a review. In: Noyes R, Roth M, Burrows G, editors. Handbook of anxiety. Volume 4. Amsterdam: Elsevier; 87-108.
  260. Oei, T.P.S., Llamas, M., & Devilly, G.J. (1999): The efficacy and cognitive processes of cognitive behaviour therapy in the treatment of panic disorder with agoraphobia. Behavioural & Cognitive Psychotherapy, 27, 63-88
  261. Olajide D, Lader M. (1987). A comparison of buspirone, diazepam and placebo in patiënts with chronic anxiety states. J Clin Psychopharmacol; 7: 148-152.
  262. Oostenbrink JB, MA Koopmanschap, FFH Rutten. (2000). Handleiding voor kostenonderzoek. Amstelveen: College voor Zorgverzekeringen, 178.
  263. Oosterbaan DB, van Balkom AJLM, Spinhoven Ph, van Oppen P, van Dyck R. (2001). Cognitive therapy versus moclobemide in social phobia: A controlled study. Clinical Psychology and Psychotherapy. 8: 263Ó73.
  264. Oppen P van, Haan E de, Balkom AJLM van, Spinhoven P, Hoogduin K, Dyck R van. (1995). Cognitive therapy and exposure in vivo in the treatment of OCD. Behav Res & Ther; 33: 379-390.
  265. Oppen, P. van, Hoekstra, R., & Emmelkamp, P.M.G. (1995). The structure of obsessive compulsive symptoms. Behaviour Research and Therapy, 33, 15-23.
  266. Öst, L.-G. & Breitholtz, E. (2000). Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. Behav Res Ther 38, 777-790.
  267. Öst, L.-G. (1986). Applied relaxation: description of a coping technique and review of controlled studies. Behav Res Ther, 25, 397-409.
  268. Ost, L-G. (1987): Applied relaxation: description of a coping technique and review of controlled studies. Behaviour Research & Therapy, 25, 397-409.
  269. Öst, L-G. (1996). One-session group treatment of spider phobia. Behaviour Research & Therapy, 34, 707-715.
  270. Öst, L-G. (1997). Rapid treatment of specific phobias. In: G.C.L. Davey (ed.): Phobias. A handbook of theory, research and treatment. Chichester, New York.
  271. Öst, L-G., Brandberg, M., & Alm, T. (1997). One versus five sessions of exposure in the treatment of flying phobia. Behaviour Research & Therapy, 35, 987-996
  272. O'Sullivan, G., Noshirvani, H., Marks, I., Monteiro, W. & Lelliott, P. (1991). Six Gyear follow Gup after exposure and clomipramine therapy for obsessive Gcompulsive disorder. J Clin Psychiatry; 52: 150n55.
  273. Otto, M.W., Pollack, M.H., Sachs, G., Reiter, S., Meltzer-Brody, S., & Rosenbaum, J. (1993): Discontinuation of benzodiazepine treatment: Efficacy of cognitive-behavioral therapy for patiënts with panic disorder. American Journal of Psychiatry, 150, 1485-1490.
  274. Paterson, (1987). Offers expert diagnosis and treatment of anxiety disorders by ... Clinical Academic Building- Suite 2200 125 Paterson Street New ... Sacker School of Medicine.
  275. Payne, H. (1992). Dance movement therapy: Theory and practice. London: Routledge.
  276. Pecknold JC, Matas M, Howarth DG. (1989). Evaluation of buspirone as an anti-anxiety agent: buspirone and diazepam versus placebo. Can J Psychiatry; 34: 766-771.
  277. Peters, R.M. (1999). The effectiveness of therapeutic touch: a meta-analytic review, vol. 12, pp. 52-61.
  278. Petruzello SJ, Landers DM, Hatfield BD, Kubitz KA, Salazar W. (1991). A metaanalysis on the anxiety-reduction effects of acute and chronic exercise ? outcomes and mechanisms, Vol 11 (3): 143-182 MAR.
  279. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. (1995). Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Brit J Psychiatry; 166: 424-443.
  280. Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL (1992). A double-blind study of adjurant buspirone hydrochloride in clomipramine-treated patiënts with obsessive compulsive disorder. J Clin Psychopharmacol; 12: 11-18.
  281. Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL. (1990). Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry; 47: 926-932.
  282. Pigott TA, Pato MT, LGHeureux F (1991). A controlled comparison of adjuvant lithium carbonate or thyoroid hormone in clomipramine-treated patiënts with obsessive compulsive disorder. J Clin Psychopharmacol; 11: 242-248.
  283. Pilowsky, I. (1967). Dimensions of hypochondriasis. British Journal of Psychiatry, 113, 39-43.
  284. Pittler, MH., Ernst, E. (2002). Kava extract for treating anxiety (Cochrane Review). In: The Cochrane Library, 1. Oxford: Update Software.
  285. Ploeg, H.M., van der, Defares, P.B. & Soielberger, C.D. (1980). Handleiding bij de Zelf Beoordelings Vragenlijst, ZBV: Een Nederlandse bewerking van de Spielberger State-Trait Anxiety Inventrory, STAI-DY. Lisse: Swets en Zeitlinger.
  286. Pollack MH, Otto MW, Worthington JJ, Gus Manfro G, Wolkow R. Sertraline in the treatment of panic diosrder. A flexible-dose trial. Arch Gen Psychiatry 1998;55:1010-1016.
  287. Pollack MH, Tesar GE, Rosenbaum JF, Spier SC. Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol 1986; 6: 302-304.
  288. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyngar MK. (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry; 62: 350-357
  289. Pop VJM, Heck van GL. (1999). Vroegdetectie van depressie op de werkplek: een onderzoek bij 4200 werknemers. i.o.v. Depressie Stichting, Utrecht.
  290. Posthuma D., (2001). Ik tel ook mee als ik plezier heb; beeldende therapie met een groep vrouwen met traumatische seksuele ervaringen. In in beeld Celine Schweizer (redactie). Houten: Bohn Stafleu Van Loghum.
  291. Rachman, S., Craske, M., Tallman, K., & Solyom, C. (1986): Does escape behavior strenghten agoraphobic avoidance? A replication. Behavior Therapy, 17, 366-384.
  292. Rakel RE. (1990). Longterm buspirone therapy for chronic anxiety: a multi-centre international study to determine safety. Southern Medical Journal; 83: 194-198.
  293. Rapee RM, Heimberg RG. (1997). A cognitive-behavioral model of anxiety in social phobia. Behav Res Ther 35: 741-56.
  294. Rapee RM, Lim L. (1992). Discrepancy between self- and observer ratings of performance in social phobics. J Abnorm Psychol 101: 728-31.
  295. Rasmussen S, Hackett E, DuBoff E, Greist JH, Halaris A, Koran L, Liebowitz MR, Lydiard B, McElroy S, Mendels J, OüConnor K. (1997). A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin psychopharmacol; 12: 309-316.
  296. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. (1996). Drug treatment of Obsessive-compulsive disorder: Long-term trial with clomipramine and selective serotonin reuptake inhibitors. Psychopharmacol Bull; 32: 167-173.
  297. Rickels K, Csanalosi I, Greisman P, et al. (1983). A controlled clinical trial of alprazolam for the treatment of anxiety. American J Psychiatry; 140: 82-85.
  298. Rickels K, Downing R, Schweizer E, et al. (1993). Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry; 50: 884-895.
  299. Rickels K, Pollack MH, Sheehan DV, Haskins JT. (2000). Efficacy of extended-release venlafaxine in nondepressed outpatiënts with generalized anxiety disorder. Am J Psychiatry; 157: 968-974.
  300. Rickels K, Schweizer E, DeMartinis N, et al. (1997). Gepitone and diazepam in generalized anxiety disorder: a placebo controlled trial. J Clin Psychopharmacology; 17: 272-277.
  301. Ritter, (1996). Graff Low, Effects of Dance/movement therapy: a meta-analysis, The arts in Psychotherapy, Vol. 23, no 3, 249-260.
  302. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. (1997). Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatrica Scandinavica; 95: 444-450.
  303. Romano S, Goodman W, Tamura R, Gonzales J, Coll Res Group. (2001). Long-term treatment of obsessive-compulsive disorder after acute repsonse: A comparison of fluoxetine versus placebo. J Clin Psychopharmacol; 21: 46-52.
  304. Roodbol, G.J.M., Rutgers, A.G. Coping, in Effectief verplegen deel 2, p 57-86 KAVANAH, Dwingeloo.
  305. Rothbaum, B.O., Meadows, E.A., Resick, P., Foy, D.W. (2000). Cognitive-Behavioral Therapy. In: E.B.
  306. Ruggiero L, Pitts CD, Dillingham K, Zaninelli R. A flexible dose study of paroxetine in the treatment of PTSD. Poster nr 602 APA 2001.
  307. Ruiz AT. (1983). A doubleblind study of alprazolam and lorazepam in the treatment of anxiety. J Clin Psychiatry; 44: 60-62.
  308. Rutten- van Mölken MPMH, Busschbach JJ van, Rutten FFH. (2001). Van kosten tot effecten. Een handleiding voor evaluatiestudies in de gezondheidszorg. Maarssen: Elsevier gezondheidszorg.
  309. Sanavio, E. (1988). Obsessions and compulsions: the Padua Inventory. Behaviour Research and Therapy, 26, 167-177.
  310. Saperston, and R. West, (Eds.) (1989). The Art and Science of Music Therapy: A Handbook. Chur, Zwitserland: Harwood Academic Publishers.
  311. Schmidt, T. & Lousberg, R. (1992). De MEGAH schaal. Lisse: Swets & Zeitlinger.
  312. Scholing A, Emmelkamp PM. (1993). Cognitive and behavioural treatments of fear of blushing, sweating or trembling. Behav Res Ther 31: 155-70.
  313. Scholing A, Emmelkamp PM. (1993). Exposure with and without cognitive therapy for generalized social phobia: effects of individual and group treatment. Behav Res Ther 31: 667-81.
  314. Scholing A, Emmelkamp PM. (1996). Treatment of fear of blushing, sweating, or trembling. Results at long¬term follow-up. Behav Modif 20: 338-56.
  315. Scholing A, Emmelkamp PM. (1996). Treatment of generalized social phobia: results at long-term follow-up. Behav Res Ther 34: 447-52.
  316. Scholing, A. & Emmelkamp, P.M.G. (1992). Self report of anxiety: A cross validation of the Lehrer Woolfolk Anxiety symptom Questionnaire in three populations. Behaviour Research and Therapy, 30, 521-531.
  317. Schweitzer E, Pohl R, Balon R. (1990). Lorazepam versus alprazolam in the treatment of panic disorder. Pharmacopsychiatry; 23: 90-93.
  318. Shalev, A.Y., Bonne, O., Eth, S. (1996). Treatment of posttraumatic stress disorder: A review. Psychosomatic Medicine, 58, 165-182.
  319. Sharp DM, Power KG, Simpson RJ, Swanson V, Moodie E, Anstee JA, Ashford JJ (1994). Fluvoxamine, placebo, and cognitive-behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia. J Anxiety Disord, 10: 219-242.
  320. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar C. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry; 59 (suppl 20): 22 - 33. (B).
  321. Sherman, J.J. (1998). Effects of psychotherapeutic treatments for PTSD: a meta-analysis of controlled clinical trials. Journal of Traumatic Stress, 11,413-35.
  322. Smeijsters, H., (2000). Handboek voor creatieve therapie. Bussum: Uitgeverij Coutinho.
  323. Smitten, M.H. ter, Smeenk, R.M.W. & Brink, W. van den (1997). Composite International Diagnostic Interview (CIDI). Basis versie 2.1. Interviewer handleiding. World Health Organization.
  324. Snyder, M., & Chlan, L. (1999). Music therapy. Annual Review of Nursing Research, 17, 1,3-19.
  325. Solomon, S.D., Davidson, J.R.T. (1997). Trauma: Prevalence, Impairment, Service use, and Cost. Journal of Clinical Psychiatry, 58, 5-11.
  326. Solomon, S.D., Gerrity, E.T., Muff, A.M. (1992). Efficacy of treatments for posttraumatic stress. Journal of Cognitive Psychotherapy: An International Quarterly, 49, 3-17.
  327. Sorby, N.G.D., W. Reavley, J.W. Huber. (1991). Self help programma for anxiety in general practice: a controlled trial of an anxiety management booklet. British Journal of General Practice, Oct; 41(351): 417-20.
  328. Speckens, A., Spinhoven P., Sloekers, P.P.A., Bolk, J., & Van Hemert, A.M. (1996). A validation study of the Whiteley Index, the Illness Attitude Scales and the Somatosensory Amplification Scale in general medical and general practice patiënts. Journal of Psychosomatic Research, 40, 95-104.
  329. Speckens, A.E.M., Hemert, A.M. van, Spinhoven, Ph., Hawton, K.E., Bolk, J.H. & Rooijmans, G.M. (1995). Cognitive behavioural therapy for medically unexplained physical symptoms: a randomised controlled trail. British Medical Journal, 311, 1328-1332.
  330. Stanton, L. & Jones, K. (1992). An introduction to dance movement therapy. London: Routledge.
  331. Starcevic, V. & Lipsitt, D.R. (eds.) (2001). Hypochondriasis: Modern perspecitves on an ancient malady. Oxford: Oxford University Press, Inc.
  332. Stein DJ, Berk M, Els C, Emsley RA, Gittelson L, Wilson D et al. (1999). A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J; 89(4):402-406.
  333. Stein DJ, Hewett K, Oldham M, Bryson H. (2000). Paroxetine in the treatment of PTSD. Poster WCBP 2001. Stein DJ, Seedat S, van der Linden GJ, Zungu-Dirway; N. Selective serotonin reuptake inhibitors in the treatment of post-traumatic stress disorder: a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol; 15 suppl 2: S1-39.
  334. Stein DJ, Seedat S, van der Linden GJ, Zungu-Dirway N. (2000). Selective serotonin re uptake inhibitors in the treatment of post-traumatic stress disorder; a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol; 15 suppl 2: S1-39.
  335. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. (1999).Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry; 156(5):756-760.
  336. Steketee G, Eisen J, Dyck I, Warshaw M, Rasmussen S. (1999). Predictors of course in obsessive-compulsive disorder. Psychiat Res; 89: 229-238.
  337. Stocchi F, Nordera G, Jokinen R, Lepola U, Bryson H, Hewett K, Iyengar M. (2001). Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder (GAD). Abstract nr 633 APA.
  338. Strand M, Hetta J, Rosen A, Sorensen S, Malmstrom R, Fabian C, Marits K, Vetterskog K, Liljestrand AG, Hegen C. (1990). A double-blind, controlled trial in priamary care patiënts with generilized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry: 51 suppl: 40-45.
  339. Sutherland SM, Tupler LA, Colkaet JT. (1996/1984). 2-Year follow-up of social phobia: status after a brief medication trial. J Neur-ment Dis: 731-738.
  340. Taylor S. (1996). Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry 27: 1-9,.
  341. Telch, M.J., Agras, W.S., Barr Taylor, C., Roth, W.T. & Gallen, C.C. (1985). Combined pharmacological and behavioral treatment for agoraphobia. Behaviour Research and Therapy, 23, 325Ó35.
  342. Terluin, B. (1998). De vierdimensionale Klachtenlijst (4DKL) in de huisartspraktijk. Psychodiagnostiek gereedschap. De Psycholoog, 33, 18-24.
  343. Tesar GE, Rosenbaum JF Pollack MH. (1991). Double-blind, placebo-controlled comparison of clonazpam and alprazolam for panic disorder. J Clin Psychiatry; 52: 69-76.
  344. Thorpe, S.J., & Salkovskis, P.M. (1997). Animal phobias. In: G.C.L. Davey (ed.) Phobias. A handbook of theory, research and treatment. Chichester, New York.
  345. Tiemens, B.G., Ormel, J., Brink, R.H.S. van den, Jenner, J.A., Meer, K. van der, Os, T.W.D.P. van, & Smit, A. (1995). Signalering van depressie en gegeneraliseerde angst in de huisartsenpraktijk. De ontwikkeling van een screeningsinstrument. Tijdschrift voor Sociale Gezondheidszorg, 73, 520-527.
  346. Tollefson GD, Birkett M, Koran L, Genduso L. (1994). Continuation treatment of OCD: Double-blind and open-label experience with fluoxetine. J Clin Psychiatry; 55 (suppl 10): 69-76.
  347. Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Dominguez RA, Koran LM, Shear KS, Goodman W, Genduso LA. (1994). A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry; 51: 559-567.
  348. Townsend, M.C. (1998). Verpleegkundige diagnostiek in de psychiatrie, Een handleiding voor het maken van een verpleegplan, tweede ed. Elsevier/De Tijdstroom, Utrecht.
  349. Turner SM, Beidel DC, Cooley-Quille MR. (1995). Two-year follow-up of social phobics treated with social effectiveness therapy. Behav Res Ther 33: 553-5.
  350. Turner SM, Beidel DC, Jacob RG. (1994). Social phobia: a comparison of behavioural therapy and atenolol. J Consulting & Clin Psychology; 62: 350-358.
  351. Tyrer, P., B. Seivewright, B. Ferguson, S. Murphy, A.L. Johnson. (1993). The Nottingham Study of Neurotic Disorder: effect of personality status on response to drug treatment, cognitive therapy and self-help over two years. British Journal of Psychiatry, 162, 219-226.
  352. Tyrer, P., B. Seivewright, B. Ferguson, S. Murphy, C. Darling, J. Brothwell, D. Kingdon, A.L. Johnson. (1990). The Nottingham Study of Neurotic Disorder: relationship between personality status and symptoms. Psychological Medicine, 20, 423-431.
  353. Uhlenhut EH, De Witt H, Balter MB et al. (1988). Risks and benefits of longterm benzodiazepine use. J Clin Psychopharmacology; 8: 161-167.
  354. Uhlenhuth EH, Matuzas W, Glasas RM, Eaton C. (1989). Response of panic disorder to fixed doses of alrazolam or imipramine. J Affect Dis; 17: 261-270.
  355. Versiani M, Nardi AE, Figueirai. (1997). Dubbelblind placebo-controlled trial with bromazepam in social phobia. Serie Psichopharmocologia-59, Journal Bras Psiquiatr; 46: 167-171.
  356. Versiani M, Nardi AE, Mundim FD, Alvees AB, Liebowitz MR, Amrein R. (1992). Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry; 161: 353-360.
  357. Visser S, Hoekstra RJ, Emmelkamp PMG. (1992). Follow-up study on behavioural treatment of obsessive-compulsive disorders. In: Ehlers A, Flegenbaum W, Florin I, Margraf J, editors. Perspectives and promises of clinical psychology. New York: Plenum; 157-170.
  358. Visser, S. & Bouman, T.K. (2001). The treatment of hypochondriasis: exposure plus response prevention versus cognitive therapy. Behaviour Research and Therapy,4, 437-457.
  359. Visser, S. & Reinders, M. (1999). Cognitieve therapie bij hypochondrie en andere somatoforme stoornissen. In: S.M. Bögels & P. van Oppen (red.) Cognitieve therapie: theorie en praktijk. Houten: Bohn Stafleu Van Loghum (p. 219-246).
  360. Visser, S. (2001). Hypochondrie. In: Spinhoven, Bouman & Hoogduin (red.) Behandelstrategieën bij somatoforme stoornissen. Houten: Bohn Stafleu Van Loghum.
  361. Vliet IM van, Den Boer JA, Westenberg HG. (1994). Psychopharmacological treatment of social phobia: a double-blind placebo-controlled study with fluvoxamine. Psychopharmacology (Berl); 115(1-2):128-134.
  362. Voert, N. ter, (2001). Creatief werk binnen de methode beeldcommunicatie. Leiden: doctoraalscriptie Universiteit Leiden.
  363. Vossen, M.L. (1998). Standaardverpleegplannen voor de GGZ.
  364. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. (1997). The effect of citalopram in panic disorder. Br J Psychiatry;170:549-553.
  365. Walker JR, Kjernisted KD. (2000). Fear: The impact and treatment of social phobia. J Psychopharmcol;14:2-S23.
  366. Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka BR, Goldner E, Johnston DC, Lavallie YJ, Nandy S, Pecknold JC, Hadrava V, Laen RM. (2000). Prevention of relapse in generalized social phobia: results of 24-week study in responders to 20 weeks sertraline treatment. J Clin Psychopharmacology, vol 20: 636-644.
  367. Warwick, H.M.C. & Salkovskis, P.M. (1990). Hypochondriasis. Behaviour Research and Therapy, 28, 105-117.
  368. Warwick, H.M.C., Clark, D.M., Cobb, A.M. & Salkovskis, P.M. (1996). A Controlled Trial of Cognitive Behavioural Treatment of Hypochondriasis. British Journal of Psychiatry, 169, 189-195.
  369. Wells A, Papageorgiou C. (2001). Social phobic interoception: effects of bodily information on anxiety, beliefs and self-processing. Behav Res Ther 39: 1-11,.
  370. Wells, A (1995). Meta-cognition and Worry: a cognitive model of generalized anxiety disorder. Behavioural and Cognitive Psychotherapy, 23, 301-320.
  371. Wells, A. (1997). Cognitive Therapy of Anxiety Disorders. Chichester: John Wiley & Sons.
  372. Wertheim- Cahen, T., (1991). Getekend bestaan: beeldend-creatieve theapie met oorlogsgetroffenen. Utrecht: ICODO.
  373. Westenberg HGM. (1999). Selective serotonin reuptake inhibitors in social anxiety disorder. In: Focus on psychiatry: social anxiety disorder. Ed. HGM Westenberg & JA den Boer. Synthesis, Amsterdam: 182-187.
  374. Wheatley D. (2001). Kava and valerian in the treatment of stress-induced insomnia. Phytother Res Sep;15(6):549-51.
  375. White, J. (1998). DStresspacD: Three-year follow-up of a controlled trial of a self-help package for the anxiety disorders. Behavioural and Cognitive Psychotherapy, 26, 133-141.
  376. White, J. (1995). Stresspac: a controlled trial of a self-help package for the anxiety disorders. Behavioural and cognitive psychotherapy, 23, 89-107.
  377. Wiborg, I.M., & Dahl, A.A. (1996): Does brief dynamic psychotherapy reduce the relapse rate of panic disorder? Archives of General Psychiatry, 53, 689-694.
  378. Willems, L.F.M., Tuender-de Haan, H.A., & Defares, P.B. (1973). Een schaal om sociale angst te meten. Nederlands Tijdschrift voor de Psychologie, 28, 415-422.
  379. Williams, J.B.W., Gibbon, M., First, M.B., Spitzer, R.L., Davies, M., Borus, J., et al. (1992). The Structured Clinical Interview for the DSM-III-R (SCID): Part II: multisite test-retest reliability. Archives of General Psychiatry, 49, 630-636.
  380. Winstead-Fry, P., Kijek. (1999). An integrative review and meta-analysis of therapeutic touch research, Alternative therapies, Vol 5, no 6, November.
  381. Wolpe, J. & Lang, P.J. (1964). Fear Survey Schedule for use in behavior therapy. Behaviour Research and Therapy, 2, 27-30.
  382. Yule, W. (Ed.) (1999). Posttraumatic stress disorders: Concepts and Therapy. New York: Wiley.
  383. Zohar J, Judge R, OCD paroxetine study group. (1996). Paroxetine versus clomipramine in the treatment of obsessive compulsive disorder. Brit J Psychiatry; 169: 468-474.

Overwegingen

Effectiviteit

Applied relaxation is een methode die door patiënten doorgaans goed wordt verdragen en die door veel behandelaars adequaat kan worden uitgevoerd.

 

Duur en wijze van toepassing.

Applied relaxation kan bij verschillende psychische klachten en stoornissen worden toegepast.

 

Duurzaamheid

De lange termijn effecten van cognitieve therapie zijn beter gedocumenteerd dan die van applied relaxation.

Autorisatiedatum en geldigheid

Laatst beoordeeld : 01-02-2010

Laatst geautoriseerd : 01-02-2010

De Multidisciplinaire Richtlijn Angststoornissen wordt op dit moment ge-update. Naar de revisie van de MDR Angststoornissen kan op de volgende wijze verwezen worden: Richtlijnherziening van de Multidisciplinaire richtlijn Angststoornissen (eerste revisie). Richtlijn voor de diagnostiek, behandeling en begeleiding van volwassen patiënten met een angststoornis.

Initiatief en autorisatie

Initiatief : Nederlandse Vereniging voor Psychiatrie

Algemene gegevens

De digitale versie van deze richtlijn is ontwikkeld vanuit het Landelijk Actieprogramma Kwaliteit geestelijke gezondheidszorg en verslavingszorg (LAK GGZ/VZ). Dit programma is een initiatief van het ministerie van VWS en wordt gecoördineerd en gefinancierd door ZonMw.

 

Kwaliteitsinstituut voor de Gezondheidszorg CBO

Het Kwaliteitsinstituut voor de Gezondheidszorg CBO, gevestigd in Utrecht, heeft tot doel individuele beroepsbeoefenaren, hun beroepsverenigingen en zorginstellingen te ondersteunen bij het verbeteren van de patiëntenzorg. Sinds zijn oprichting in 1979 heeft het CBO zich ontwikkeld tot een toonaangevend en ook internationaal erkend instituut dat via programma's en projecten ondersteuning en begeleiding biedt bij systematisch en gestructureerd meten, verbeteren, herontwerpen en borgen van kwaliteit van de patiëntenzorg.

 

Trimbos-instituut

Het Trimbos-instituut is het landelijk kennisinstituut voor de geestelijke gezondheidszorg, de verslavingszorg en de maatschappelijke zorg.

De missie van het Trimbos-instituut is kennis over geestelijke gezondheid creëren en doen toepassen in beleid en praktijk van de geestelijke gezondheidszorg, de verslavingszorg en de maatschappelijke zorg.

Samenstelling werkgroep

De multidisciplinaire richtlijn Angststoornissen is op initiatief en onder auspiciën van de Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ en de daaronder ressorterende Commissie Cliëntenparticipatie tot stand gebracht door de werkgroep Angststoornissen waarin de deelnemende verenigingen en organisaties hebben samengewerkt.

Methodologische en organisatorische ondersteuning en begeleiding werden verzorgd door het Kwaliteitsinstituut voor de Gezondheidszorg CBO en het Trimbos-instituut.

 

Landelijke Stuurgroep Multidisciplinaire Richtlijnontwikkeling in de GGZ

Voorzitter          

R.M.W. Smeets, Raad van Bestuur GGZ Friesland

Vice-voorzitter 

Prof.dr. G. Hutschemaekers, De Gelderse Roos, Arnhem

Secretaris           

Mw. dr. A. Eland (tot januari 2002) en dr. A.L.C.M. Henkelman, Trimbos-instituut

Leden   

Ir. T.A. van Barneveld, Kwaliteitsinstituut voor de Gezondheidszorg CBO

Mw. H. Blankman, Federatie Verpleegkunde in de GGZ (FVGGZ)

Mw. dr. J.H. Dekker, Nederlands Huisartsen Genootschap (NHG)

Dr. P.M.A.J. Dingemans, Nederlands Instituut van Psychologen (NIP)

Dr. P.A. de Groot t, Nederlandse Vereniging voor Psychiatrie (NVvP)

Prof.dr. R.W. Trijsburg, Nederlandse Vereniging voor Psychotherapie (NVP)

Agendaleden   

Prof. Dr. W.J.J. Assendelft, Nederlands Huisartsen Genootschap (NHG)

Dr. dr. G.A. van Essen, Nederlands Huisartsen Genootschap (NHG)

Mw. dr. G.H.M.M. ten Horn     

Drs. J. Penninga, Ministerie van Volksgezondheid, Welzijn en Sport

Adviseur             

Prof. dr. J.A. Swinkels, AMC De Meren, Amsterdam/Trimbos-instituut

 

Commissie Cliëntenparticipatie

Voorzitter          

Mw. dr. G.H.M.M. ten Horn     

Secretaris           

Mw. drs. C. van der Veen, Trimbos-instituut

Leden   

Mw H. Boumans, Ypsilon

Mw. E. Dangerman, Stichting Borderline

Mw. T. de Vent, Stichting Labyrint/ In Perspectief

Mw. drs. A.M. Dijkman, Vereniging voor Manisch Depressieve en Betrokkenen (VMDB)

T. Festen            

Mw. H. van ’t Kooten, Vereniging voor Manisch Depressieve en Betrokkenen (VMDB)

B.H. Kraaijenbrink, Stichting Anorexia en Boulimia Nervosa

Mw. I. Lüneburg, Landelijke Vereniging Balans

Mw. M. Mannak-Bouman, Stichting Labyrint/In Perspectief

Mw. I. Poort, Nederlandse Vereniging voor Autisme (NVA)

Mw. drs. M.K. Taams, Stichting FobieVrienden

Mw. M. Van der Linden, Angst, Dwang en Fobiestichting

Mw. L. van ’t Veen, Cliëntenbond in de GGZ

M. Vermeulen, Anoiksis

T. Vriens, Stichting Pandora

Mw. drs. J. Zwanikken-Leenders, GGZ Den Bosch

 

Werkgroep Angststoornissen

Voorzitter

Prof. dr. Ph. Spinhoven, hoogleraar Universiteit Leiden

Leden

Prof. dr. A.J.L.M. van Balkom, psychiater, Vrije Universiteit Medisch Centrum, Amsterdam

Mw. M. Boon, creatief therapeut, Sinai Centrum, Amersfoort

Mw. drs. C.A.M. Bouwmans, gezondheidswetenschapper, iMTA, Rotterdam

F.E. ten Broeke, psycholoog

Prof. dr. R. van Dyck, hoogleraar psychiatrie, Vrije Universiteit Medisch Centrum, Amsterdam

Prof. dr. P.M.G. Emmelkamp, psycholoog

Mw. dr. M.H. Grol, huisarts

Mw. dr. L. Hakkaart-van Roijen, gezondheidseconoom, iMTA, Rotterdam

Mw. drs. H. de Kam, verpleegkundig stafmedewerker, Symforagroep Zon en Schild, Amersfoort

Dr. C.W. Korrelboom, psychotherapeut, Parnassia Psycho-medisch Centrum, Den Haag

Drs. J.C.G.J. Oomen, psychotherapeut, Vincent van Gogh Instituut, Venray

G.J.M. Roodbol MScN, verpleegkundig specialist, Universitair Medisch Centrum St. Radboud, Nijmegen

Mw. drs. E.M.A.A. Rozenbroek, apotheker, Apotheek Koek, Amsterdam

Mw. drs. M. Scholte, onderzoeker, Nederlands Instituut voor Zorg en Welzijn, Utrecht

Mw. drs. M.K. Taams, cliëntvertegenwoordiger, Stichting Fobie Vrienden, Hillegom

Dr. B. Terluin, huisarts, senior onderzoeker, Emgo-instituut, Amsterdam

Mw. S.C.D. Timmer, maatschappelijk werk

Mw. M. Ulrich, cliëntvertegenwoordiger

Drs. D.W.F. Veldhorst, bedrijfsarts, ‘Arboreijn' Arbo en reïntegratiebedrijf, Ede

Dr. S. Visser, klinisch psycholoog/psychotherapeut, Angstpolikliniek GGZ Buitenamstel, Amsterdam

Mw. dr. I.M. van Vliet, psychiater, Leids Universitair Medisch Centrum, Leiden

 

Met dank aan:

Mw.drs. M. Scholte, NIZW, leverde de werkgroep belangrijke bijdragen voor het hoofdstuk "Ondersteunende interventies".

 

Adviseurs

Mw. drs. M.M. Kroeze, adviseur Kwaliteitsinstituut voor de Gezondheidszorg CBO, Utrecht, adviseur (tot mei 2002)

Mw. drs. A. Hagemeijer               , adviseur Kwaliteitsinstituut voor de Gezondheidszorg CBO, Utrecht, adviseur (vanaf mei 2002)

Mw. dr. M.J.C. van Hattum, wetenschappelijk medewerker, Trimbos instituut, Utrecht secretaris (tot september 2002)

Methode ontwikkeling

Evidence based

Werkwijze

Voor artikelen betreffende preventie of therapie:

A1

systematische reviews die ten minste enkele onderzoeken van A2-niveau betreffen, waarbij de resultaten van afzonderlijke onderzoeken consistent zijn

A2

gerandomiseerd vergelijkend klinisch onderzoek van goede kwaliteit (gerandomiseerde, dubbelblind gecontroleerde trials) en van voldoende omvang en consistentie

B

gerandomiseerde klinische trials van matige kwaliteit of onvoldoende omvang of ander vergelijkend onderzoek (niet-gerandomiseerd, vergelijkend cohortonderzoek, patiëntcontroleonderzoek)

C

niet-vergelijkend onderzoek

D

mening van deskundigen, bijvoorbeeld de werkgroepleden

 

Voor artikelen betreffende diagnostiek:

A1 onderzoek naar de effecten van diagnostiek op klinische uitkomsten bij een prospectief gevolgde goed gedefinieerde patiëntengroep met een tevoren gedefinieerd beleid op grond van de te onderzoeken testuitslagen, of besliskundig onderzoek naar de effecten van diagnostiek op klinische uitkomsten, waarbij resultaten van onderzoek van A2-niveau als basis worden gebruikt en voldoende rekening wordt gehouden met onderlinge afhankelijkheid van diagnostische tests

A2 onderzoek ten opzichte van een referentietest, waarbij van tevoren criteria zijn gedefinieerd voor de te onderzoeken test en voor een referentietest, met een goede beschrijving van de test en de onderzochte klinische populatie; het moet een voldoende grote serie van opeenvolgende patiënten betreffen, er moet gebruikgemaakt zijn van tevoren gedefinieerde afkapwaarden en de resultaten van de test en de 'gouden standaard' moeten onafhankelijk zijn beoordeeld. Bij situaties waarbij multipele, diagnostische tests een rol spelen, is er in principe een onderlinge afhankelijkheid en dient de analyse hierop te zijn aangepast, bijvoorbeeld met logistische regressie

B vergelijking met een referentietest, beschrijving van de onderzochte test en populatie, maar niet de kenmerken die verder onder niveau A staan genoemd

C niet-vergelijkend onderzoek

D mening van deskundigen, bijvoorbeeld de werkgroepleden

 

Niveau van de conclusie op basis van de literatuuranalyse:

1

gebaseerd op minimaal één systematische review (A1) of ten minste twee onafhankelijk van elkaar uitgevoerde onderzoeken van niveau A1 of A2

2

gebaseerd op ten minste twee onafhankelijk van elkaar uitgevoerde onderzoeken van niveau B

3

gebaseerd op één onderzoek van niveau A2 of B, of op onderzoek(en) van niveau C

4

gebaseerd op (gepubliceerde) mening van deskundigen, bijvoorbeeld de werkgroepleden